Your browser is no longer supported. Please, upgrade your browser.
Settings
GHDX Genomic Health, Inc. daily Stock Chart
GHDX [NASD]
Genomic Health, Inc.
Index- P/E- EPS (ttm)-0.20 Insider Own2.00% Shs Outstand35.09M Perf Week0.37%
Market Cap1.35B Forward P/E52.01 EPS next Y0.74 Insider Trans-16.10% Shs Float34.47M Perf Month20.84%
Income-6.80M PEG- EPS next Q0.07 Inst Own91.40% Short Float1.93% Perf Quarter17.08%
Sales349.40M P/S3.85 EPS this Y73.30% Inst Trans0.17% Short Ratio3.82 Perf Half Y30.81%
Book/sh5.69 P/B6.75 EPS next Y62.56% ROA-3.00% Target Price32.42 Perf Year32.34%
Cash/sh3.72 P/C10.33 EPS next 5Y5.50% ROE-3.70% 52W Range26.54 - 39.17 Perf YTD12.22%
Dividend- P/FCF52.40 EPS past 5Y-19.50% ROI-4.20% 52W High-2.00% Beta0.65
Dividend %- Quick Ratio4.90 Sales past 5Y7.70% Gross Margin82.90% 52W Low44.63% ATR1.02
Employees863 Current Ratio4.90 Sales Q/Q10.20% Oper. Margin-2.30% RSI (14)74.66 Volatility1.94% 3.08%
OptionableYes Debt/Eq0.00 EPS Q/Q-352.50% Profit Margin-2.00% Rel Volume0.92 Prev Close38.38
ShortableYes LT Debt/Eq0.00 EarningsMay 02 AMC Payout- Avg Volume174.52K Price38.38
Recom2.90 SMA205.67% SMA5013.79% SMA20017.85% Volume121,888 Change0.01%
Dec-20-17Downgrade William Blair Outperform → Mkt Perform
Dec-13-17Downgrade JP Morgan Neutral → Underweight
May-03-17Downgrade Raymond James Outperform → Mkt Perform
Jan-18-17Initiated Deutsche Bank Hold $31
Feb-11-16Reiterated Canaccord Genuity Buy $44 → $38
Jan-11-16Downgrade Piper Jaffray Overweight → Neutral
Jan-07-16Reiterated Barclays Underweight $25 → $27
Jan-06-16Upgrade Canaccord Genuity Hold → Buy $26 → $44
Nov-23-15Upgrade UBS Neutral → Buy $29 → $38
Nov-04-15Upgrade Raymond James Mkt Perform → Outperform
Sep-02-15Initiated Barclays Underweight $25
Aug-28-15Upgrade Raymond James Underperform → Mkt Perform
Aug-05-15Reiterated Canaccord Genuity Hold $28 → $26
Mar-10-15Initiated UBS Neutral $34
Aug-11-14Reiterated Canaccord Genuity Hold $30 → $27
Aug-02-13Reiterated MLV & Co Hold $30 → $35
Feb-21-12Downgrade GARP Research Buy → Neutral
Feb-08-12Downgrade MLV & Co Buy → Hold $31.50 → $30
Dec-12-11Reiterated Ladenburg Thalmann Buy $26 → $32
Nov-02-11Upgrade Ladenburg Thalmann Neutral → Buy $26
May-24-18 04:23PM  Intuitive Surgical (ISRG) Gains on Strength in Robotics Zacks
May-23-18 11:00AM  Here's Why You Should Buy Cooper Companies (COO) Stock Now Zacks
May-22-18 10:42AM  Allscripts Acquires HealthGrid to Improve Patient Outcome Zacks
May-21-18 08:19AM  Cerner-VA Pact to Use EHR Platform for Better Veteran Service Zacks
08:00AM  New Data Reinforce Positive Impact of the Oncotype DX® Genomic Prostate Score Test in Guiding Treatment Decisions PR Newswire
May-18-18 09:55AM  Varian Medical (VAR) Merges With Brazil MOH to Fight Cancer Zacks
09:42AM  Here's Why You Should Steer Clear of Cerner (CERN) for Now Zacks
08:50AM  Here's Why You Should Sell DENTSPLY SIRONA (XRAY) Stock Now Zacks
08:44AM  Weakness Seen in Anika Therapeutics (ANIK) Estimates: Should You Stay Away? Zacks
May-17-18 11:23AM  Thermo Fisher (TMO) Gains on Latest Buyouts Despite Cost Woes Zacks
10:28AM  Abaxis (ABAX) to be Acquired by Zoetis, Shares All-Time High Zacks
09:15AM  Veeva Systems Launches Veeva Nitro, Boosts MedTech Analytics Zacks
May-16-18 09:58AM  Can The Uptrend Continue for Genomic Health (GHDX)? Zacks
May-15-18 09:35AM  Baxter (BAX) Gets FDA Nod for Spectrum IQ, Secures Infusions Zacks
May-14-18 11:00AM  Here's Why You Should Sell Fresenius Medical (FMS) Stock Now Zacks
May-11-18 09:16AM  Here's Why You Should Invest in Varian Medical (VAR) Now Zacks
May-10-18 10:10AM  Here's Why You Should Invest in Intuitive Surgical Right Now Zacks
May-09-18 08:00AM  Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference PR Newswire
04:38AM  Edited Transcript of GHDX earnings conference call or presentation 2-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-04-18 02:52PM  Genomic Health Starts the Year off Right Motley Fool
May-03-18 11:54AM  Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Low Zacks +6.73%
May-02-18 06:02PM  Genomic Health: 1Q Earnings Snapshot Associated Press
04:05PM  Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress PR Newswire
Apr-26-18 08:00AM  Large Independent Study Using the Oncotype DX® Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
Apr-25-18 08:00AM  Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018 PR Newswire
Apr-24-18 07:35AM  Consolidated Research: 2018 Summary Expectations for AeroVironment, PS Business Parks, Genomic Health, Digi International, Sensient Technologies, and PolyOne Fundamental Analysis, Key Performance Indications GlobeNewswire
Apr-09-18 04:58AM  Why Is Genomic Health (GHDX) Up 1.6% Since Its Last Earnings Report? Zacks
Mar-30-18 08:23AM  Intrinsic Calculation For Genomic Health Inc (NASDAQ:GHDX) Shows Investors Are Overpaying Simply Wall St.
08:00AM  Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect Test in Patients with Metastatic Castration-Resistant Prostate Cancer PR Newswire
Mar-15-18 08:00AM  Landmark TAILORx Results Aid in Assessing the Effect of Chemotherapy in Women with Early-stage Breast Cancer and Oncotype DX Breast Recurrence Score® Results of 11 to 25 PR Newswire
Mar-12-18 03:17PM  Genomic Health Hits its Inflection Point Motley Fool
Mar-09-18 05:56PM  Edited Transcript of GHDX earnings conference call or presentation 8-Mar-18 1:30pm GMT Thomson Reuters StreetEvents +5.08%
09:14AM  Genomic Health (GHDX) Q4 Earnings & Revenues Miss Estimates Zacks
Mar-08-18 09:59AM  Genomic Health misses Street 4Q forecasts Associated Press -5.23%
08:03AM  When Will Genomic Health Inc (NASDAQ:GHDX) Become Profitable? Simply Wall St.
08:00AM  Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook PR Newswire
06:45AM  Genomic Health, Inc. to Host Earnings Call ACCESSWIRE
Mar-02-18 02:12PM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Mar-01-18 01:04AM  Biocartis Group NV: BIOCARTIS ANNOUNCES 2017 RESULTS AND 2018 OUTLOOK GlobeNewswire
Feb-28-18 08:15AM  Consolidated Research: 2018 Summary Expectations for Genomic Health, Worthington Industries, BMC Stock, Alexander & Baldwin, ACI Worldwide, and La-Z-Boy Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-26-18 08:00AM  Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect Test to Predict Treatment Response in Metastatic Disease PR Newswire
Feb-22-18 08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018 PR Newswire -6.21%
Feb-19-18 07:21AM  Interested In Genomic Health Inc (NASDAQ:GHDX)? Heres What Its Recent Performance Looks Like Simply Wall St.
Feb-06-18 09:30AM  Genomic Health (GHDX) Oncotype DX GPS Test Results Positive Zacks
Feb-05-18 08:00AM  Oncotype DX® Genomic Prostate Score Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care PR Newswire
Dec-28-17 08:30AM  Analysis: Positioning to Benefit within Genomic Health, Worthington Industries, Rambus, OMNOVA Solutions, CAI International, and Rudolph Technologies Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-21-17 08:00AM  Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-20-17 07:49AM  Innovation, Partnership Aid Genomic Health, Cost Woe Remains Zacks
Dec-18-17 08:38AM  Genomic Health at a 52-Week High: What's Driving the Stock? Zacks
Dec-15-17 07:19AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : December 15, 2017 Capital Cube +6.82%
Dec-14-17 01:56PM  Why Genomic Health, Inc. Skyrocketed Today Motley Fool +18.86%
Dec-12-17 09:17AM  Genomic Health (GHDX) Oncotype DX Score Test Data Positive Zacks
Dec-11-17 01:53PM  ETFs with exposure to Genomic Health, Inc. : December 11, 2017 Capital Cube
08:00AM  Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum PR Newswire
Dec-08-17 08:19AM  Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus Zacks
Dec-06-17 08:00AM  Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score Test for Potential Drug Development PR Newswire
Dec-01-17 10:38AM  ETFs with exposure to Genomic Health, Inc. : December 1, 2017 Capital Cube
Nov-30-17 09:38AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017 Capital Cube
08:00AM  Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging PR Newswire
Nov-29-17 11:50AM  Genomic Health-Cleveland Diagnostics Deal to Boost Test Suite Zacks
Nov-28-17 08:00AM  Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests PR Newswire
Nov-21-17 08:00AM  Genomic Health to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-17-17 03:00PM  Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes Zacks
Nov-16-17 10:39AM  Genomic Health, Inc. Turns a Profit (With an Asterisk) Motley Fool
01:02AM  Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE GlobeNewswire
Nov-12-17 04:41AM  Edited Transcript of GHDX earnings conference call or presentation 8-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 08:06AM  Genomic Health (GHDX) Swings to Earnings in Q3, Revenues Lag Zacks
Nov-08-17 04:43PM  Genomic Health reports 3Q loss Associated Press
04:05PM  Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress PR Newswire
Nov-01-17 08:00AM  Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017 PR Newswire
Oct-05-17 11:38AM  Genomic Health's Cost Pressure Mounts, Cancer Tests Strong Zacks
Sep-27-17 08:09AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 27, 2017 Capital Cube
Sep-26-17 10:52AM  ETFs with exposure to Genomic Health, Inc. : September 26, 2017 Capital Cube
06:56AM  Medicare reimbursement cuts slam stocks of lab services companies MarketWatch
Sep-25-17 04:25PM  Quest, LabCorp Are Big 'Losers' Under Medicare Overhaul: Analyst Investor's Business Daily
Sep-14-17 06:17PM  ETFs with exposure to Genomic Health, Inc. : September 14, 2017 Capital Cube
10:31AM  Genomic Health Ties up With Biocartis, Boosts Oncotype DX Zacks
Sep-13-17 11:52AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube
01:00AM  Genomic Health and Biocartis Announce Agreement to Develop an Idylla IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access PR Newswire
Sep-11-17 08:00AM  Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017 PR Newswire
Sep-05-17 09:47AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 5, 2017 Capital Cube
Aug-31-17 08:00AM  Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress PR Newswire
Aug-24-17 08:00AM  Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017 PR Newswire
Aug-13-17 09:10AM  Edited Transcript of GHDX earnings conference call or presentation 1-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:02PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : August 12, 2017 Capital Cube
Aug-03-17 10:00AM  Genomic Health, Inc.: Still Waiting for Reimbursement Motley Fool
Aug-02-17 11:08AM  Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2 Zacks -5.46%
08:06AM  Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings? Zacks
Aug-01-17 10:12PM  Genomic Health reports 2Q loss Associated Press
04:05PM  Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress PR Newswire
11:00AM  Investor Network: Genomic Health, Inc. to Host Earnings Call ACCESSWIRE
Jul-28-17 09:36AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : July 28, 2017 Capital Cube
Jul-20-17 08:00AM  Genomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017 PR Newswire
Jul-12-17 08:00AM  Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer PR Newswire
Jun-29-17 03:02PM  ETFs with exposure to Genomic Health, Inc. : June 29, 2017 Capital Cube
Jun-21-17 08:29AM  Genomic Health Cancer Tests Strong, Operating Expenses a Woe Zacks
Jun-14-17 09:47AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-13-17 03:41AM  Why Is Genomic Health (GHDX) Up 7.1% Since the Last Earnings Report? Zacks
Jun-02-17 08:00AM  Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types PR Newswire
Jun-01-17 12:06PM  Genomic Health to Unveil Oncotype DX Study Results at ASCO Zacks
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Popovits Kimberly JPresident and CEOMay 14Option Exercise17.1810,000171,800246,157May 16 06:41 PM
Popovits Kimberly JPresident and CEOMay 14Sale38.0910,000380,877236,157May 16 06:41 PM
Shak StevenChief Scientific OfficerMay 09Option Exercise17.335,50095,315341,416May 11 03:10 PM
Shak StevenChief Scientific OfficerMay 09Sale36.645,500201,543335,916May 11 03:10 PM
Vaughn James JChief Commercial OfficerMay 02Sale32.501,49748,65329,655May 04 08:59 PM
Popovits Kimberly JPresident and CEOApr 16Option Exercise17.1815,000257,700251,157Apr 18 04:33 PM
Popovits Kimberly JPresident and CEOApr 16Sale33.1915,000497,880236,157Apr 18 04:33 PM
Popovits Kimberly JPresident and CEOMar 14Option Exercise17.185,00085,900241,157Mar 16 06:54 PM
Popovits Kimberly JPresident and CEOMar 14Sale32.015,000160,048236,157Mar 16 06:54 PM
Cole G BradleyCOOMar 13Option Exercise17.335,00086,65049,754Mar 15 04:31 PM
Cole G BradleyCOOMar 13Sale32.805,000164,01444,754Mar 15 04:31 PM
BAKER BROS. ADVISORS LPDirectorMar 09Option Exercise18.5049,500915,75011,369,282Mar 12 06:04 PM
Cole G BradleyCOOFeb 20Option Exercise17.335,00086,65049,754Feb 22 04:19 PM
Leber LauraChief Communication OfficerFeb 20Sale32.923,374111,08016,531Feb 22 04:24 PM
Febbo Phillip G.Chief Medical OfficerFeb 20Sale32.844,942162,29021,387Feb 22 04:19 PM
Cole G BradleyCOOFeb 20Sale32.895,000164,47444,754Feb 22 04:19 PM
Popovits Kimberly JPresident and CEOFeb 14Option Exercise17.1810,000171,80075,849Feb 15 04:02 PM
Popovits Kimberly JPresident and CEOFeb 14Sale32.9310,000329,33665,849Feb 15 04:02 PM
Popovits Kimberly JPresident and CEOJan 16Option Exercise17.1810,000171,80051,719Jan 18 09:30 PM
Popovits Kimberly JPresident and CEOJan 16Sale34.9910,000349,88541,919Jan 18 09:30 PM
Cole G BradleyCOOJan 09Option Exercise17.335,00086,65045,346Jan 10 09:17 PM
Cole G BradleyCOOJan 09Sale35.515,000177,56640,346Jan 10 09:17 PM
Vaughn James JChief Commercial OfficerJan 02Option Exercise17.332,16937,58930,481Jan 04 07:54 PM
Vaughn James JChief Commercial OfficerJan 02Sale34.093,004102,40627,477Jan 04 07:54 PM
Febbo Phillip G.Chief Medical OfficerDec 19Option Exercise27.005,000135,00023,134Dec 20 04:35 PM
Febbo Phillip G.Chief Medical OfficerDec 19Sale36.995,334197,29817,800Dec 20 04:35 PM
Leber LauraChief Communication OfficerDec 15Option Exercise17.339,000155,97024,754Dec 18 07:52 PM
Leber LauraChief Communication OfficerDec 15Sale35.009,000315,00015,754Dec 18 07:52 PM
Popovits Kimberly JPresident and CEODec 14Option Exercise17.2820,000345,53561,919Dec 18 07:51 PM
Leber LauraChief Communication OfficerDec 14Option Exercise21.5212,000258,24027,754Dec 18 07:52 PM
Leber LauraChief Communication OfficerDec 14Sale32.0012,000384,00015,754Dec 18 07:52 PM
Popovits Kimberly JPresident and CEODec 14Sale31.5020,000630,00041,919Dec 18 07:51 PM
Cole G BradleyCOODec 12Option Exercise17.335,00086,65044,935Dec 13 04:14 PM
Cole G BradleyCOODec 12Sale29.945,000149,70939,935Dec 13 04:14 PM
Cole G BradleyCOONov 07Option Exercise17.335,00086,65044,935Nov 09 04:59 PM
Cole G BradleyCOONov 07Sale31.475,000157,33039,935Nov 09 04:59 PM
Vaughn James JChief Commercial OfficerNov 02Option Exercise17.3392416,01328,999Nov 08 05:29 PM
Vaughn James JChief Commercial OfficerNov 02Sale32.511,37944,82727,620Nov 08 05:29 PM
Vaughn James JChief Commercial OfficerNov 01Option Exercise17.333,90767,70833,692Nov 08 05:29 PM
Vaughn James JChief Commercial OfficerNov 01Sale32.585,617183,00128,075Nov 08 05:29 PM
Cole G BradleyCOOOct 10Option Exercise17.335,00086,65044,935Oct 11 05:55 PM
Cole G BradleyCOOOct 10Sale31.935,000159,63739,935Oct 11 05:55 PM
Popovits Kimberly JPresident and CEOSep 14Option Exercise17.335,00086,65046,132Sep 18 04:02 PM
Popovits Kimberly JPresident and CEOSep 14Sale31.005,000154,98941,132Sep 18 04:02 PM
Cole G BradleyCOOSep 12Option Exercise17.335,00086,65044,935Sep 14 05:12 PM
Cole G BradleyCOOSep 12Sale31.865,000159,28839,935Sep 14 05:12 PM
Popovits Kimberly JPresident and CEOAug 14Option Exercise17.335,00086,65084,057Aug 16 08:02 PM
Popovits Kimberly JPresident and CEOAug 14Sale30.225,000151,11179,057Aug 16 08:02 PM
Cole G BradleyCOOAug 08Option Exercise17.335,00086,65044,935Aug 09 07:51 PM
Vaughn James JChief Commercial OfficerAug 08Option Exercise23.316,500151,51537,785Aug 09 07:52 PM
Vaughn James JChief Commercial OfficerAug 08Sale30.598,000244,72429,785Aug 09 07:52 PM
Cole G BradleyCOOAug 08Sale30.575,000152,84639,935Aug 09 07:51 PM
Febbo Phillip G.Chief Medical OfficerJul 19Sale33.573,174106,53817,800Jul 21 04:20 PM
Cole G BradleyCOOJul 11Option Exercise17.335,00086,65044,935Jul 13 05:23 PM
Cole G BradleyCOOJul 11Sale32.535,000162,66739,935Jul 13 05:23 PM
Popovits Kimberly JPresident and CEOJul 05Option Exercise17.331,46825,44080,525Jul 06 07:28 PM
Popovits Kimberly JPresident and CEOJul 05Sale32.671,46847,95279,057Jul 06 07:28 PM
Popovits Kimberly JPresident and CEOJul 03Option Exercise17.333,53261,21082,589Jul 06 07:28 PM
Popovits Kimberly JPresident and CEOJul 03Sale32.563,532114,98879,057Jul 06 07:28 PM
Shak StevenChief Scientific OfficerJun 23Option Exercise23.315,000116,550336,924Jun 27 06:11 PM
Shak StevenChief Scientific OfficerJun 23Sale33.275,000166,371331,924Jun 27 06:11 PM
Cole G BradleyCOOJun 13Option Exercise17.335,00086,65044,935Jun 15 04:40 PM
Cole G BradleyCOOJun 13Sale31.675,000158,34239,935Jun 15 04:40 PM
Popovits Kimberly JPresident and CEOJun 05Option Exercise17.335,00086,65084,057Jun 07 07:07 PM
Popovits Kimberly JPresident and CEOJun 05Sale32.325,000161,58279,057Jun 07 07:07 PM
BAKER BROS. ADVISORS LPDirectorMay 31Option Exercise18.1349,500897,43511,359,212Jun 01 05:19 PM